Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from Analysts at Brookline Capital Management

Equities research analysts at Brookline Capital Management began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report issued on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $9.00 price target on the stock. Brookline Capital Management’s price target suggests a potential upside of 411.36% from the stock’s previous close.

QNCX has been the topic of a number of other reports. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Rodman & Renshaw began coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price target on the stock. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Finally, Maxim Group initiated coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective on the stock. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Quince Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.67.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $1.76 on Wednesday. The company’s 50-day moving average is $1.59 and its two-hundred day moving average is $1.02. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a market capitalization of $77.44 million, a price-to-earnings ratio of -1.42 and a beta of 0.74.

Institutional Trading of Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC increased its holdings in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.